CorMedix
CRMD
7.28
0.00
0.00%
CorMedix
US · CRMD
#3663 by market cap
7.28
0.00
0.00%
Live - 5344 symbols - heartbeat 300s ago
· 2026-10-08 09:20
Pre-market
7.29
+0.14%
After-hours
7.30
+0.28%
Overnight
7.28
0.00%
- Market cap
- 567.43M
- P/E (TTM)i
- 3.34
- P/Bi
- 1.23
- EPSi
- 2.04
- Div yieldi
- 0.00%
- 52W posi
- 17%
Reader sentiment
Are you bullish or bearish on CRMD?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Ownership Signal how this is computed
Distributing
- The number of reporting institutions decreased by 2 in the most recent period (2026/Q3).
- Total institutional ownership fell 0.8 percentage points.
Institutional ownership
- Held by institutions
- 57.00% -0.75pp
- Institutions
- 222 -2
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
AlignedInstitutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
Mutual Fund39.08%
VC/PE Fund8.05%
Individual/Insider7.42%
Hedge Fund5.27%
Public Company1.97%
Private Company1.59%
Government Pension Fund0.69%
Insurance Company0.25%
Other35.63%
Top holders as of 2026-06-30
BlackRock
8.11% · 6.32M sh
Deep Track Capital, LP
8.05% · 6.27M sh
Shaibatalhamd Abdalkader
5.93% · 4.62M sh
Vanguard Capital Management, LLC
4.64% · 3.62M sh
State Street Global Advisors
2.97% · 2.32M sh
Royce & Associates, LP
2.79% · 2.18M sh
UBS Asset Management
2.56% · 1.99M sh
Geode Capital Management, LLC
2.50% · 1.95M sh
Oberweis Asset Management, Inc.
1.70% · 1.32M sh
Alyeska Investment Group, L.P.
1.09% · 850.00K sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 21 buys · 29 sells
| Name | Role | Stake |
|---|---|---|
| Joseph Todisco | Chief Executive Officer | 0.51% |
| Myron Kaplan | Independent Chairperson | 0.30% |
| Kaufman Zelnick | Executive Vice President | 0.13% |
| Steven Lefkowitz | Independent Director | 0.13% |
| Janet Dillione | Independent Director | 0.11% |
| Elizabeth Masson-Hurlburt | Executive VP and Head of Clinical & Medical Affairs | 0.11% |
| Alan Dunton | Independent Director | 0.05% |
| Gregory Duncan | Independent Director | 0.05% |
| Robert Stewart | Independent Director | 0.05% |
| Matthew David | Chief Financial Officer | 0.03% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-09-17 | Janet Dillione | Independent Director | Derivative Exercise and Retained | +48,909 | -- |
| 2026-08-28 | Elizabeth Masson-Hurlburt | Executive VP and Head of Clinical & Medical Affairs | Sale to Issuer | -8,076 | $8.30 |
| 2026-08-28 | Susan Blum | EVP & Chief Financial Officer | Sale to Issuer | -8,424 | $8.30 |
| 2026-08-28 | Kaufman Zelnick | Executive Vice President | Sale to Issuer | -8,424 | $8.30 |
| 2026-02-03 | Joseph Todisco | Chief Executive Officer | Other Acquisition | +77,156 | -- |
| 2026-02-03 | Elizabeth Masson-Hurlburt | Executive VP and Head of Clinical & Medical Affairs | Other Acquisition | +36,006 | -- |
| 2026-02-03 | Kaufman Zelnick | Executive Vice President | Other Acquisition | +36,006 | -- |
| 2026-01-25 | Myron Kaplan | Independent Chairperson | Other Acquisition | +30,453 | -- |
| 2026-01-25 | Alan Dunton | Independent Director | Other Acquisition | +30,453 | -- |
| 2026-01-25 | Janet Dillione | Independent Director | Other Acquisition | +30,453 | -- |
| 2026-01-25 | Steven Lefkowitz | Independent Director | Other Acquisition | +30,453 | -- |
| 2026-01-25 | Robert Stewart | Independent Director | Other Acquisition | +30,453 | -- |
| 2026-01-25 | Gregory Duncan | Independent Director | Other Acquisition | +30,453 | -- |
| 2026-01-22 | Joseph Todisco | Chief Executive Officer | Sale to Issuer | -27,306 | $7.27 |
| 2026-01-22 | Joseph Todisco | Chief Executive Officer | Other Acquisition | +225,900 | -- |
| 2026-01-22 | Elizabeth Masson-Hurlburt | Executive VP and Head of Clinical & Medical Affairs | Sale to Issuer | -10,778 | $7.27 |
| 2026-01-22 | Elizabeth Masson-Hurlburt | Executive VP and Head of Clinical & Medical Affairs | Other Acquisition | +93,010 | -- |
| 2026-01-22 | Susan Blum | EVP & Chief Financial Officer | Sale to Issuer | -9,767 | $7.27 |
| 2026-01-22 | Susan Blum | EVP & Chief Financial Officer | Other Acquisition | +72,820 | -- |
| 2026-01-22 | Kaufman Zelnick | Executive Vice President | Sale to Issuer | -8,803 | $7.27 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-08 09:20:33 · For reference only, not investment advice and not tailored to your situation.